APP’s cefepime is AP-rated, bar-coded and latex-free. Cefepime hydrochloride for injection is indicated in the treatment of the following infections: pneumonia, empiric therapy for febrile neutropenic patients, urinary tract infections (including pyelonephritis), skin and skin structure infections, and intra-abdominal Infections.
Tom Silberg, president of APP, said: “The launch of Cefepime further bolsters our leadership position as a provider of the broadest portfolio of generic anti-infective injectable products.”